We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Astex Pharmaceuticals to Present AT26893 at EASL
News

Astex Pharmaceuticals to Present AT26893 at EASL

Astex Pharmaceuticals to Present AT26893 at EASL
News

Astex Pharmaceuticals to Present AT26893 at EASL

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Astex Pharmaceuticals to Present AT26893 at EASL"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Astex Pharmaceuticals, Inc. has announced that it will present data on AT26893, a novel, first-in-class, direct acting antiviral agent (DAA) against Hepatitis C Virus (HCV) at the 47th Annual Meeting of the European Association for the Study of the Liver (EASL): The International Liver Congress™, April 18 to 22, 2012 in Barcelona, Spain.

The following presentations are scheduled for Friday, April 20th from 12:30 to 2:00 pm during the poster session: Viral Hepatitis C: Experimental (virology)

• Abstract No. 19057: Fragment based discovery and cellular validation of a novel allosteric binding site on the full length HCV NS3/4a enzyme.
• Abstract No. 19064: Pre-clinical characterization of a novel allosteric inhibitor of the HCV full length NS3/4a protein.

The NS3 protein is essential for viral replication and represents a validated HCV therapeutic target.

Astex has used its fragment-based drug discovery approach, Pyramid™, to discover and target a novel allosteric binding site on the full length HCV NS3 protease - helicase enzyme.

Compounds binding at this site have a novel mode of action and a different resistance profile compared to NS3 active-site protease inhibitors and these data will be presented at EASL.

Astex scientists will also present data on the characterization of AT26893 that has entered formal preclinical development in preparation for an IND filing.

This research program, which has been supported with £2 million of funding from the Wellcome Trust Seeding Drug Discovery initiative, is wholly owned by Astex Pharmaceuticals.

Advertisement